*Email: Laurent.Petit@minakem.com
CONCLUSION
We have demonstrated a simple route to access racemic salbu-
tamol hemisulfate. The use of a lipophilic protecting group
facilitated the isolation of the intermediates. The experimental
protocols developed are simple and reproducible thus allowing
ACKNOWLEDGMENTS
This work was fully funded by Minakem. The authors wish to
thank Melina Morival, Marion Dujardin and Solenne Kowalkowski
implementation on preparative scale using standard equipment; for their analytical support. Dr. Shri Hedge, Dr. Pierre-Georges
Echeverria and Dr. Oscar Rebolledo are warmly thanked for proof-
reading and improving the manuscript. The support and empower-
ment of Frédéric Gauchet and Dr. Olivier Jentzer are sincerely
acknowledged.
isolations of the intermediates and final product were performed
without the need for column chromatography.
ASSOCIATED CONTENT
Supporting Information
REFERENCES AND NOTES
The Supporting Information is available free of charge and includes
detailed experimental procedures, 1H and 13C NMR spectra, IR
spectra, DSC thermograms, processed MS data and GC or HPLC
chromatograms of the isolated compounds.
AUTHOR INFORMATION
Corresponding Author
Highlights
Even simple molecules can be challenging to make.
Literature process descriptions are not always reproducible.
Protecting groups can also be implemented to modify the physicochemical properties of
molecules.
1 Page, C.; Humphrey, P. Br. J. Clin. Pharmacol. 2013, 75, 1213 and references therein.
2 Strong, P.; Ito, K.; Murray, J.; Rapeport, G. Drug Discov. Today, 2018, 23, 1705.
4
Wang, C.; Xu, J. Wang, R.; Yang, L.; Shi, Z.; Xu, Y.; Zhao, J.; Zhang, X.; Ye, X.; Bai, C.; Song, Y.; Kang, J.; Wang, Q.; Ran, P.; Zhou, Y.;
Shen, H.; Ding, L.; Wen, F.; Yang, T.; Huang, K.; Lin, Y.; Lu, Y.; Zhang, H.; Bu, X.; An, L.; Zhang, S.; Cao, Z.; Yang, Y.; Yao, W.; Chen, Y.;
Sun, T.; Guo, Y.; Shan, G.; Zhang, B.; Yang, T.; Zhang, X.; Zhan, Q.; Cao, B.; Dai, H.; Wu, S.; Zhu, J.; Xiao, F.; Peng, X.; Xiao, D.; Chen, C.-S.;
Wang, Z.; Liang, L.; He, J. Lancet. 2018, 391, 1642.
5 Bakale, R. P.; Wald, S. A.; Butler, H. T.; Gao, Y.; Hong, Y.; Nie, X.; Zepp, C. M. Clinical Reviews in Allergy and immunology, 1996, 14, 7.
6
Leitch, D. C.; Greene, T. F.; O’Keffe, R.; Lovelace, T. C.; Powers, J. D.; Searle, A. D. Org. Process Res. Dev., 2017, 21, 1806 and references
therein.
7 Babad, E.; Carruthers, N. I.; Jaret, R. S.; Steinman, M. Synthesis, 1988, 966. See also CN104356009 for a similar approach.
8 (a) Vekariya, R. H.; Aube, J. Org. Lett. 2016, 18, 3534; (b) Wilkinson, M. C. Org. Lett. 2011, 13, 2232; (c) Kangani, C. O.; Day, B. W. Org. Lett.
2008, 10, 2645.
9
Krishnan, L.; Sum, P.-E.; Horne, J. M.; Tuper, A. J.; McCauley, J. J. III; Pilcher, A. S.; Michaud, A. P.; Daigneault, S.; Bernatchez, M. Patent
Application WO2006130418A1, 2006.
10 Ruohonen, J. Finnish Patent FI51345B, 1974.
12
Jacobsen, J. R.; Choi, S. K.; Combs, J.; Fournier, E. J. L.; Klein, U.; Pfeiffer, J. W.; Thomas, G. R.; Yu, C.; Moran, E. J. Bioorg. Med. Chem.
Lett. 2012, 22, 1213 and references therein.
13 Floyd, M. B.; Du, M. T.; Fabio, P. F.; Jacob, L. A.; Johnson, B. D. J. Org. Chem. 1985, 50, 5022
14 Eftekhari-Sis, B.; Zirak, M.; Akbari, A. Chem. Rev. 2013, 113, 2958 and references therein.
15 Hyde, A. M.; Zultanski, S. L.; Waldman, J. H.; Zhong, Y.-L.; Shevlin, M.; Peng, F. Org. Proc. Res. Dev. 2017, 21, 1355.
16 Delhaye, L.; Ceccato, A.; Jacobs, P.; Köttgen, C.; Merschaert, A. Org. Proc. Res. Dev. 2007, 11, 160.
4